BBNX
Beta Bionics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.40
P/S
4.40
EV/EBITDA
-6.59
DCF Value
$-79.22
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.4%
Operating Margin
-71.5%
Net Margin
-73.0%
ROE
-24.4%
ROA
-22.3%
ROIC
-23.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $32.1M | $-13.5M | $-0.30 |
| FY 2025 | $100.3M | $-73.2M | $-1.81 |
| Q3 2025 | $27.3M | $-14.2M | $-0.33 |
| Q2 2025 | $23.2M | $-16.9M | $-0.39 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
5.60
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.